- Research article
- Open Access
- Open Peer Review
Fatigue in fibromyalgia: a conceptual model informed by patient interviews
BMC Musculoskeletal Disordersvolume 11, Article number: 216 (2010)
Fatigue is increasingly recognized as an important symptom in fibromyalgia (FM). Unknown however is how fatigue is experienced by individuals in the context of FM. We conducted qualitative research in order to better understand aspects of fatigue that might be unique to FM as well as the impact it has on patients' lives. The data obtained informed the development of a conceptual model of fatigue in FM.
Open-ended interviews were conducted with 40 individuals with FM (US [n = 20], Germany [n = 10] and France [n = 10]). Transcripts were analyzed using qualitative methods based upon grounded theory to identify key themes and concepts.
Participants were mostly female (70%) with a mean age of 48.7 years (range: 25-79). Thirty-one individuals (i.e., 77.5%) spontaneously described experiencing tiredness/lack of energy/fatigue due to FM. Participants discussed FM fatigue as being more severe, constant/persistent and unpredictable than normal tiredness. The conceptual model depicts the key elements of fatigue in FM from a patient perspective. This includes: an overwhelming feeling of tiredness (n = 17, 42.5%), not relieved by resting/sleeping (n = 15, 37.5%), not proportional to effort exerted (n = 25, 62.5%), associated with a feeling of weakness/heaviness (n = 20, 50%), interferes with motivation (n = 22, 55%), interferes with desired activities (n = 27, 67.5%), prolongs tasks (n = 15, 37.5%), and makes it difficult to concentrate (n = 21, 52.5%), think clearly (n = 12, 30%) or remember things (n = 9, 22.5%).
The majority of individuals with FM who participated in this study experience fatigue and describe it as more severe than normal tiredness.
Fibromyalgia (FM) is a chronic disorder characterised by widespread pain and tenderness [1, 2], with an estimated prevalence in adults ranging from 0.5-10% worldwide [3–9] with a predominance among females . In addition to chronic widespread musculoskeletal pain, symptoms of fatigue, sleep disorders, headaches, memory or concentration problems, mood disturbances, and stiffness are also commonly associated with FM [1, 2, 4, 11].
Previous focus groups found that, in addition to pain and sleep disturbance, fatigue was perceived by patients to be one of the three most bothersome symptoms of FM . A Delphi study by 23 FM expert clinicians identified fatigue as being the second most important domain to measure (after pain), and it was subsequently rated as third most important (after pain and overall FM) by a Delphi study involving patients . At the Outcome Measures in Rheumatology (OMERACT) 7 workshop composed of clinicians, researchers, regulatory and industry representatives, 94% of participants agreed that fatigue was an essential domain to measure in FM clinical trials . Thus, there is growing consensus among patients, as well as clinical experts, that fatigue is a key symptom to assess in clinical trials of FM. This is further supported by other publications of qualitative FM patient research [14–18].
Like pain, the measurement of fatigue relies on patient report. Recent guidance from regulators highlights that patient input (ideally in the form of qualitative research) is critical when developing or selecting a patient-reported outcome (PRO) measure for a specific condition [19, 20]. Existing fatigue measures such as the Multidimensional Fatigue Inventory (MFI)  and the Multidimensional Assessment of Fatigue (MAF) have been used extensively in FM clinical trials [22–27]. However, no existing measures were developed with FM specifically in mind and qualitative interviews with FM patients were not included in the development of any existing fatigue measures. Thus, in-depth, qualitative research with FM patients is needed that focuses on exploring the experience of fatigue in FM in order to provide an understanding of how it can be best measured (which may be through using existing instruments or through the development of a new, FM-specific measure of fatigue).
The current project seeks to explore fatigue in detail through in-depth, qualitative interviews with individuals who have FM. The results will inform the development of a conceptual model of fatigue in FM. The conceptual model will define the properties of FM fatigue (and the relationship between each concept and the symptom) and will then be used to support the selection or development of PROs for this symptom.
Sample and study design
Open-ended, qualitative interviews were conducted with 40 individuals with FM in the US (5 male, 15 female), Germany (5 male, 5 female) and France (2 male, 8 female) (Table 1). Participants were recruited through primary care physicians/general practitioners, pain specialists and rheumatology specialists and the sample included individuals from three different countries/cultures/languages to increase the likelihood that findings could be generalized across cultures/languages. Purposive sampling ensured the inclusion of individuals from a range of educational backgrounds and ethnicities . In each country, a minimum of 20% of participants were male, and a minimum of 30% had an education level of high school (or equivalent) or less. In the US, a minimum of 10% were non-Caucasian to ensure ethnic diversity.
Participants were at least 18 years of age, met the American College of Rheumatology (ACR) criteria for FM (1) and were willing and able to participate in a 90-minute interview. Participants were excluded if they had significant physical or psychiatric co-morbidities (including severe pain not related to FM) that might have interfered with their experience of, or ability to talk about, FM. Of note, participants were not required to have fatigue - they were only required to have a diagnosis of FM because this study was part of a larger project looking at other FM domains in addition to fatigue.
Ethics approval of the study protocol, documents and procedures was granted by Copernicus, a US centralized Independent Review Board, and written informed consent was obtained from all participants prior to entry into the study.
All interviews were conducted by an experienced qualitative interviewer, who was a native speaker of the language in which the interview was performed. Using a semi-structured interview guide, questions were initially open-ended to ensure participants were not biased by the topics of interest (e.g., "tell me about your experience of having fibromyalgia?"). Direct questioning was only used when topics of importance did not arise in response to the open-ended questions.
Participants were first asked to talk about their general experience of FM and then asked to describe good and bad days with FM. Participants were also asked what three things bothered them most about having FM. These exploratory questions were followed by two creative tasks that encouraged participants to talk in a spontaneous, more creative manner about their FM. First, prior to interview, participants were asked to create a drawing or collage representing their FM which was discussed during the interview. In the second task, participants were asked: "if your FM was an animal, what animal would it be?" Participants were asked open questions about "FM" generally rather than fatigue specifically so that if fatigue was discussed, it was identified spontaneously by the participant indicating the importance of the symptom to FM patients.
Only after these open-ended questions and creative tasks did the interview progress to more focused questions relating to FM fatigue (if not already discussed). This methodology gives participants the opportunity to mention FM fatigue spontaneously and also to mention concepts/symptoms/domains of importance which may not have been in the discussion guide .
At the end of each interview, participants were asked to list the symptoms of FM they experience and to rate their pain, fatigue, cognition and functioning using Visual Analogue Scales (VAS) and Numerical Rating Scales (NRS). Each interview lasted approximately 90 minutes. Revising the guide was considered after the first five interviews; no revisions were required.
Patient-reported questions and demographics
As well as completing the VAS and NRS symptom questions, participants also provided information regarding their age, gender, number and age of children, living situation (e.g. living alone, with a partner, etc), highest level of education, work status and ethnicity. The French participants were not asked for ethnicity as it is considered culturally inappropriate.
Collection of clinician-reported information
To verify the patient-reported data and to provide additional clinical information, the recruiting physicians were asked for background clinical information including: year of diagnosis, current FM treatments and details of co-morbidities. The clinicians chose which of a list of 20 'symptoms and syndromes' commonly associated with FM (e.g. fatigue, stiffness, depression) were present in their patient. There was also space for the clinician to add any other symptoms/syndromes not listed.
All interviews were audio-taped and transcribed verbatim with any identifiable information removed during transcription. Qualitative analysis of the verbatim transcripts was conducted in the original language version of the transcript by an analyst who was also a native speaker. Coding of quotes by concept/domain involved assigning appropriate codes to patient statements determined by the underlying concept such as 'difficulty remembering' and then grouping concepts into domains, for example, 'cognitive limitations'. This analysis approach is based on a Grounded Theory approach [30–33] and Atlas Ti software (Atlas.ti GmbH Berlin, Germany, version 5.2) was used. The French and German transcripts were coded in both their original language and their English translation (to retain cultural meaning and identify any language subtleties), and the developed code list compared with codes from the US interviews to identify consistency in the concepts emerging from the analysis. The coding scheme, driven by the participants' experience was developed iteratively, changed dynamically as more data was analysed. The reliability of codes and definitions were confirmed through extensive discussion and consensus among analysis team members. Codes were then organised into higher order domains/concepts.
Analysis was conducted to determine whether conceptual saturation was achieved. Saturation has been defined as the point at which no new concepts or sub-concepts emerge with the addition of more interviews [31, 34]. In the current research, saturation in the US sample was examined by comparing the first 10 transcripts with the next 10 to identify if any concepts arising in the second set of 10 interviews had not arisen in the first 10 interviews. If new concepts had emerged, additional interviews would have been conducted and the saturation checking process repeated. For country-level saturation, the concepts arising from the French and German transcripts were compared to those arising from the US interviews.
Results and Discussion
Background characteristics of the sample
Consistent with the sampling targets and prevalence of FM , 28/40 participants (70%) were female, mean age was 48.7 years (range: 25-69 years old) and patients had a range of education levels. Of the 30 participants who provided ethnicity information, the majority were Caucasian (n = 25, 83%).
Clinician-reported background clinical data
Participants had been diagnosed with FM for a mean of 6.6 years (SD = 5.20, range = 1-18 years). The most common clinician-reported FM-related "symptoms and syndromes" were fatigue (n = 40, 100%), stiffness (n = 39, 98%), sleep disorders (n = 37, 93%), joint aches (n = 36, 90%) and tenderness to touch (n = 34, 85%). Depression was identified in 37.5% (n = 15). Moreover, depression was present among French (n = 7, 70%) and US (n = 8, 40%) participants but was not reported for any German participants. With the exception of depression, there were no patterns of particular symptoms/syndromes being more frequently reported for any one country sample. The majority of participants (n = 30, 75%) had no co-morbidities unrelated to FM.
Mean scores for the quantitative patient-reported questions are presented in Figure 1. The total mean pain severity score (rated on a VAS) was 5.97, with no major differences among countries. The remaining PRO items used a 0-10 NRS scale with 10 indicating greater difficulty/severity. For all of the NRS items, the mean scores were between 4 and 6 and there were no notable differences among the country samples for most items.
Qualitative interview findings: experience of fibromyalgia
When asked, "tell me about your experience of FM", pain was the most common spontaneously reported concept (n = 31, 78%), followed by fatigue (n = 17, 43%), sleeping problems (n = 7, 18%) and mobility problems (n = 4, 10%). Participants were asked to state the three things that bothered them the most about having FM. Of the 35 who answered the question, 31 (89%) mentioned pain. The second most commonly mentioned concept was fatigue/tiredness/lack of energy mentioned by 18/35 (51%) participants (11/17 in the US; 2/10 in Germany; and 5/8 in France). The next most commonly mentioned concept was functional limitations arising from FM, mentioned by 9/35 (26%) participants.
Pain and tiredness/fatigue were the most common concepts/themes described when participants discussed their homework collages/drawings. Pain-related concepts were mentioned by 18/40 (45%) participants who chose/drew pictures of people in pain or indicated on their collage an image that represented pain. Fatigue/tiredness was mentioned by 10/40 (25%) - nine of whom were from the US (and one from France). These participants chose/drew pictures that depicted for example, people sleeping, animals carrying heavy loads and characters walking up steep hills. No German participants mentioned fatigue or tiredness in the spontaneous discussion of their homework as they focused primarily on pain. In the second creative task, participants had to think of an animal that represented their FM and what their reasons were behind their chosen animal. Of the 38 participants who completed the task, 20 (53%) chose an animal that related to fatigue/tiredness e.g. sloth or tortoise because these animals were considered 'slow' or 'lazy'. Fourteen (37%) chose an animal that related to pain (e.g. porcupine because of their spines, a lion because a roar symbolized the pain they were in), and six (16%) chose an animal related to the unpredictable and unpleasant nature of FM (e.g. snake 'because you never know when it is going to strike'). Of note, some participants chose more than one animal (e.g. one to represent pain and one to represent fatigue/tiredness) or also referenced more than one concept when explaining their choice of animal.
Qualitative interview findings: patient experience of fibromyalgia fatigue
A conceptual model of FM fatigue was developed based on the qualitative findings and on the previous qualitative research that was reviewed [11, 12, 14, 15] (Figure 2). FM fatigue was described as an overwhelming feeling of tiredness that was not relieved by sleep or rest and is often not in proportion to the effort exerted (i.e. participants described becoming tired after doing very little). Many described their fatigue as 'feeling weak' or their body feeling heavy and almost all participants talked about having to force themselves to do things or described having difficulty getting motivated to do things. Participants differentiated between FM fatigue and normal tiredness by referring to the fact that FM fatigue limited them in doing daily activities or caused difficulty concentrating, thinking clearly and/or remembering things. Detailed findings to support each of these FM fatigue characteristics are provided in Table 2, each with sample participant quotes.
Overwhelming feeling of tiredness
Seventeen participants (43%) described how at times they would become overwhelmed by their fatigue (15 spontaneously and two when probed). Eight of these participants (20% of the total sample) were, at times, overwhelmed to the point that they were unable to do anything.
Not relieved by resting or sleeping
Fifteen participants (38%) described still experiencing tiredness or fatigue, even after a good night's sleep.
Not proportional to effort exerted
Twenty-five participants (63%) talked about becoming tired very easily. For example, some individuals talked about being exhausted after doing hardly anything.
Feeling of weakness or heaviness
Eleven participants (28%) talked about their body feeling heavy, weak or not having any strength. Many of these individuals felt so weak that it was difficult to do daily activities.
Difficult to get motivated
Thirty-three participants (82.5%) talked about fatigue as not having the motivation to do things or having to force themselves to do things. Sixteen (40%) also discussed the concept of motivation in relation to having difficulty getting out of bed in the morning or 'getting going' in the morning. Others discussed the amount of effort required to do things or of needing to force themselves to do things.
Difficulty doing the things they want to do
The majority of participants (24/40, 60%) across all three countries spontaneously talked about fatigue/tiredness making it difficult to do the things that they want or need to do; one further individual talked about this when probed. Activities affected by fatigue included strenuous physical activities (e.g. playing sports, yard-work), cognitive tasks (e.g. paying bills) and simple self-care activities (e.g. pouring a cup of coffee, getting dressed).
Having to do things more slowly
Fifteen participants (38%) talked specifically about having to do things slowly, or taking longer to do things due to tiredness or fatigue. In some cases this seemed to be related to the feeling of heaviness or weakness.
Difficult to concentrate, think or remember things
Many participants (n = 27, 68%) talked about a mental or cognitive component to their fatigue. Twenty-one participants (53%) talked about fatigue/tiredness affecting their ability to concentrate, nine (23%) talked about difficulty remembering things, 12 (30%) talked about having difficulties thinking clearly and eight (20%) mentioned having trouble staying focused. As examples of activities affected by cognition problems some referred to paperwork, others described having difficulty holding simple conversations.
Terms used to refer to fatigue/tiredness/exhaustion
We were interested to know if participants distinguish between "fatigue" that might result from FM and normal tiredness. We were also interested to know if participants use the term "fatigue" to refer to something more severe than normal tiredness. Throughout the interviews, participants spontaneously used many different terms to describe their FM-related fatigue/tiredness. Table 3 summarizes the terms participants used most commonly to describe fatigue. At some point in the interview almost all participants talked either of 'feeling tired' (n = 27, 68%), being 'fatigued' (n = 14, 35%), having 'a lack of energy'/'no energy'/'little energy' (n = 20, 50%) or feeling 'exhausted' (n = 13, 33%). Some talked about feeling 'worn out' (n = 12, 30%) or 'feeling weak', (n = 11, 28%); others talked about feeling 'overwhelmed' (n = 15, 38%) by their fatigue. In the French sample, 'fatigué' was used by all participants to refer to their tiredness/fatigue. This term is usually translated as meaning 'tired' or 'tiredness', but in some contexts could also be translated as meaning 'fatigue' - we have only translated it as meaning tired. Also of note, in German there is a word that is typically translated as meaning 'tired/tiredness' and another word translated as 'exhausted'. However, no word that could be directly translated as meaning 'fatigue', distinct from these two terms was referred to. In the German sample 'tired' was by far the most common term.
Different participants often used the same term to refer to different things; for example some participants considered 'energy' to refer to the mental component of fatigue, while others related 'energy' to the physical component of fatigue. Furthermore, many participants seemed to use the different terms interchangeably and understood them all to be related to the same concept - for example, when describing their tiredness participants would often describe it as "a lack of energy'. Nevertheless, whichever words participants used to talk about their fatigue, all agreed it was worse than normal tiredness and referred to the characteristics in the model presented in this study.
Qualitative interview findings: relationship between fatigue and sleep problems
Almost all participants (n = 38, 95%) reported sleep problems due to their FM, most commonly because of pain. Participants were asked whether or not the fatigue/tiredness they experienced was related to sleep problems. Four concepts emerged: 1) the quality of sleep was perceived by participants as impacting the severity of fatigue the following day; 2) fatigue however, often occurred irrespective of sleep quality; 3) difficulty sleeping occurred irrespective of how tired a person was; and 4) some individuals experienced daytime sleepiness; however most distinguished daytime sleepiness from FM-fatigue/tiredness. These findings suggest that while sleep problems and fatigue are related, the experience of FM-fatigue was not perceived as being entirely explained by the quantity or quality of sleep.
Qualitative interview findings: saturation analysis
In the US sample, saturation of all concepts was achieved in the first 10 US interviews - no new concepts or terms for talking about fatigue arose from the second 10 US interviews that had not arisen in the first 10 interviews. Country-level saturation was also attained across the three samples - no new fatigue sub-concepts emerged from the analysis of the French and German transcripts that had not been mentioned in the US interviews.
Qualitative interview findings: gender and country sub-group analysis
Analysis of gender differences was conducted to examine the similarities/differences in the way men and women talked about FM and their fatigue. Men and women described the fatigue experience and its impact in much the same way. There was some evidence that men focused more on pain associated with their FM, whereas women talked more about fatigue. Analysis of any differences by country/language was also conducted; although fatigue was frequently and spontaneously reported in all three countries, US participants talked the most about their fatigue, followed by the German sample. French participants talked about fatigue the least. However, all concepts included in the model were mentioned by participants in all three countries, and were clearly pertinent across all country samples. Participants from all countries consistently talked about the impact on daily activities or difficulties with concentration, thinking clearly and/or remembering things as being delineating factors between FM fatigue and "normal" tiredness.
In addition, the clinician-reported data showed that more French and US patients experienced depression than German patients. Although depression and fatigue is strongly linked , our analysis revealed that there were no sub-concepts of fatigue or FM impact that were mentioned by only depressed patients. This suggests that the concepts identified by participants in this study were relevant for all and not just those who had depression.
The primary objective of this research was to better understand the patient experience of FM fatigue through open-ended, qualitative research, as advocated by regulators and experts in PRO development [19, 36, 37]. Findings suggest that, while widespread pain is the primary symptom of FM, fatigue appears to be the second most important symptom and one that has a considerable impact on patients' lives. Although fatigue was not an inclusion criterion in the present study, all participants experienced fatigue. Fatigue was often one of the first problems that participants mentioned when asked open-ended questions. In some cases participants described their fatigue as being worse than their pain because of associated daily activity limitations. These findings are consistent with, and build upon, previous exploratory focus groups, which highlighted the importance of fatigue in FM . In the focus groups, fatigue was described as one of the worst symptoms of FM and was seen as a constant presence that necessitated pacing the activities of their lives. This theme is consistent with the findings in the present research where participants reported having to do things more slowly due to their fatigue. In an earlier focus-group, participants also complained about a lack of energy that accompanied an overwhelming feeling of constant fatigue, consistent with this research. Thus, the current research is consistent with the previous research into FM fatigue [5, 11, 14–18] and provides strong evidence that the majority of individuals with FM experience fatigue which has a substantial impact on daily activities and wellbeing.
The finding that men seemed to focus more on pain, whereas women talked more about fatigue, may indicate that it is more socially acceptable for women to report fatigue. Further investigation of this gender difference is warranted. The reasons for the differences between the three countries in the frequency of fatigue being reported are unclear, and caution must also be applied in drawing conclusions from a small qualitative sample. The differences could be due to: (1) country differences in fatigue being a recognized symptom of FM; (2) language differences (in German and French there is only one word for both fatigue and tiredness - the absence of a 'clinical' sounding word such as fatigue might make patients more reluctant to report tiredness/fatigue); or (3) cultural difference in willingness to report fatigue. However, a significant proportion of the French and German samples experienced fatigue, and the impact on their lives was similar to that of the US patients. Quantitative studies looking at these differences in reporting fatigue are required to provide an understanding of whether the gender and country differences reported here are replicated in larger samples, or if they are an artefact of this small, qualitative sample [5, 38, 39].
To build on this current work, it would be interesting to compare the way FM patients talk about fatigue compared to patients with other severe articular diseases (e.g. rheumatoid arthritis), given that both groups of patients report this symptom . A comparative qualitative study with patients who have similar conditions would be warranted to understand these differences and generate a real conceptual view of the specificity of fatigue for these comparable conditions.
The qualitative findings reported here highlight the challenges of developing a measure of fatigue that has strong content validity. Thus, a possible solution to the challenge of measuring FM fatigue might be to ask individuals about all of the different characteristics of fatigue outlined in the model, and to phrase the questions using several of the different descriptors commonly used by patients.
In conclusion, this study demonstrated that in addition to pain, fatigue was an important symptom for individuals with FM. Individuals with FM used many terms to talk about the concept of fatigue including 'tired', 'fatigue', 'no energy', and feeling 'worn out', or 'exhausted'. There was consensus among participants that FM-related tiredness or lack of energy is worse than normal tiredness. The conceptual model of FM fatigue captures elements that distinguish FM fatigue from normal tiredness from a patient perspective. This conceptual model is currently being used to support the development of a new PRO for fibromyalgia fatigue.
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990, 33: 160-172. 10.1002/art.1780330203.
Jackel WH, Genth E: [Fibromyalgia]. Z Rheumatol. 2007, 66: 579-590. 10.1007/s00393-007-0229-6.
White KP, Harth M: Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep. 2001, 5: 320-329. 10.1007/s11916-001-0021-2.
Wolfe F, Ross K, Anderson J, Russell IJ, Herbert L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995, 38: 19-28. 10.1002/art.1780380104.
Branco JC, Bannwarth B, Failde I, Abello CJ, Blotman F, Spaeth M, et al.: Prevalence of Fibromyalgia: A Survey in Five European Countries. Semin Arthritis Rheum. 2010, 39 (6): 448-453. 10.1016/j.semarthrit.2008.12.003.
Raspe H: [Rheumatism epidemiology in Europe]. Soz Praventivmed. 1992, 37: 168-178. 10.1007/BF01624572.
Carmona L, Ballina J, Gabriel R, Laffon A: The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis. 2001, 60: 1040-1045. 10.1136/ard.60.11.1040.
Salaffi F, De Angelis R, Grassi W: Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005, 23: 819-828.
Coster L, Kendall S, Gerdle B, Henriksson C, Henriksson KG, Bengtsson A: Chronic widespread musculoskeletal pain - a comparison of those who meet criteria for fibromyalgia and those who do not. Eur J Pain. 2008, 12: 600-610. 10.1016/j.ejpain.2007.10.001.
Yunus MB: Gender differences in fibromyalgia and other related syndromes. J Gend Specif Med. 2002, 5: 42-47.
Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, et al.: Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008, 73: 114-120. 10.1016/j.pec.2008.06.005.
Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey LJ, et al.: Identifying the Clinical Domains of Fibromyalgia: Contributions From Clinician and Patient Delphi Exercises. Arthritis Rheum. 2008, 59: 952-960. 10.1002/art.23826.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, et al.: Fibromyalgia syndrome. J Rheumatol. 2007, 34: 1415-1425.
Cunningham MM, Jillings C: Individuals' descriptions of living with fibromyalgia. Clin Nurs Res. 2006, 15: 258-273. 10.1177/1054773806291853.
Hellstrom O, Bullington J, Karlsson G, Lindqvist P, Mattsson B: A phenomenological study of fibromyalgia. Patient perspectives. Scand J Prim Health Care. 1999, 17: 11-16. 10.1080/028134399750002827.
Cudney SA, Butler MR, Weinert C, Sullivan T: Ten rural women living with fibromyalgia tell it like it is. Holist Nurs Pract. 2002, 16: 35-45.
Schaefer KM: The lived experience of fibromyalgia in African American women. Holist Nurs Pract. 2005, 19: 17-25.
Sturge-Jacobs M: The experience of living with fibromyalgia: confronting an invisible disability. Res Theory Nurs Pract. 2002, 16: 19-31. 10.1891/rtnp.220.127.116.11994.
US FDA Draft Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009, [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf]
Committee for Medicinal Products for Human Use (CHMP): Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMEA/CHMP/EWP/139391/2004. 2005
Mease PJ, Clauw DJ, Gendreau RM: The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial [erratum in J Rheumatol. 2009;36:661]. J Rheumatol. 2009, 36: 398-409. 10.3899/jrheum.080734.
Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al.: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005, 52: 1264-1273. 10.1002/art.20983.
Arnold LM, Russell IJ, Diri E: A 14-week, randomized, doubleblinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008, 9: 792-805. 10.1016/j.jpain.2008.03.013.
Mease P, Russell IJ, Arnold LM: A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008, 35: 502-514.
Crofford LJ, Mease PJ, Simpson SL: Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month double-blind, placebo-controlled trial with pregabalin. Pain. 2008, 136: 419-431. 10.1016/j.pain.2008.02.027.
Arnold LM, Crofford LJ, Martin SA: The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med. 2007, 8: 633-638. 10.1111/j.1526-4637.2007.00332.x.
Bartels EM, Danneskiold-Samsoe B: Histological abnormalities in muscle from patients with certain types of fibrositis. Lancet. 1986, 8484: 755-757. 10.1016/S0140-6736(86)91779-4.
Field PA, Morse JA: Nursing Research: The Application of Qualitative Research. 1985, London: Croom Held
Pope C, Mays N: Reaching the parts other methods cannot reach: an introduction to qualitative methods in health and health services research. BMJ. 1995, 311: 42-45.
Bowen GA: Grounded Theory and Sensitizing Concepts. International Journal of Qualitative Methods. 2006, 5: 1-9.
Glaser B, Strauss AL: The constant comparative methods of qualitative analysis. Discovery of Grounded Theory. 1967, New York: Aldine de Gruyter, 101-116.
Glaser BG, Strauss AL: The Discovery of Grounded Theory. 1967, New York: Aldine
Strauss AL, Corbin J: Basics of Qualitative research techniques and Procedures for Developing Grounded Theory. 1998, USA: Sage
Guest G, Bunce A, Johnson L: How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006, 18: 59-82. 10.1177/1525822X05279903.
Jacobsen PB, Donovan KA, Weitzner MA: Distinguishing fatigue and depression in patients with cancer. Semin Clin Neuropsychiatry. 2003, 8: 229-240.
Leidy NK, Vernon M: Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008, 26: 363-370. 10.2165/00019053-200826050-00002.
Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al.: Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007, 10 (Suppl 2): S125-S137. 10.1111/j.1524-4733.2007.00275.x.
Wolfe F, Hawley DJ, Wilson K: The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol. 1996, 23: 1407-1417.
Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998, 41: 778-799. 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V.
Walker EA, Keegan D, Gardner G, Sullivan M, Katon WJ, Bernstein D: Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability. Psychosom Med. 1997, 59: 565-571.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/11/216/prepub
The authors would like to thank the individuals with fibromyalgia who participated in the study. The authors would also like to acknowledge the contributions of Sabine Bielfeldt, Crystal Tellefsen and Eva Seignobos in conducting some of the interviews. They would also like to thank Laura-Jayne Hunter for her input into the qualitative analysis and both Tara Symonds and Linda Abetz for guidance and advice throughout the project.
Dr. Williams' involvement was supported in part by grant U01AR55069 (NIAMS/NIH).
Ms Humphrey and Mr Arbuckle received research/grant support from Pfizer and were contracted by Pfizer to assist in the present study.
All authors contributed to the study design, provided input into the writing of the protocol, interview guide and study documents, were involved in the interpretation of the results, reviewed the conceptual model and were involved in the drafting of the manuscript. All authors read and approved the final draft.